Gene Therapy 2.0: Harnessing Cutting-Edge Technologies for Precision Medicine

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 03 | 02 | Page :
    By

    Gaurav Kumar Mahto,

  • Tanya Sharma,

  • Shubam Singh,

  • Kamalesh Mistry,

  • Md. Aftab Alam,

  • Neha Nahid,

  1. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India
  2. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India
  3. Student, Bachelor of Pharmacy, Deen Dayal Rustogi college of pharmacy, Khandwela Distt, Near Haily Mandi, Haryana, India
  4. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India
  5. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India
  6. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India

Abstract

Somatic gene therapy has become the standard form of gene therapy; this creates the Gene Therapy 2.0 era. This new and distinct time consists in the new-generation genome-editing tools and markers, more efficient systems for gene delivery, and personalized medicine approaches that raise the efficacy and safety of the treatment. Base and prime editing are two types of CRISPR-based gene editing tools have provided high precision and reduced off-target effects while editing the targeted genes. These RNA based therapeutics include mRNA therapy, antisense-oligonucleotide therapy, RNAi therapy which add more dimension to the list of treatable diseases and aliments. The advancements in growth of viral and non viral vectors like adeno-associated viruses, lentiviral vectors, lipid nanoparticles and exosome based carriers make the gene transfer more efficient and have minimum immunogenic responses. Actual use of Gene Therapy 2.0 is already seen by successful treatments for monogenic diseases like spinal muscular atrophy, hemophilia, and inherited retinal diseases. Further, new therapeutics include oncology treatments, neurodegenerative disorders and & rare genetic disorders which expand the therapeutic section. However, some resistant problems are immunological responses, toxicity of vectors, and ethical issues about germline modifications. Governments such as the USA (FDA) and Europe (EMA) have continue to modify its policies about gene based therapeutic products. Now apart from artificial intelligence, the computational modeling is being used in gene therapy to increase the efficiency and accuracy of the treatment. As progress is made, Gene Therapy 2.0 is set to revolutionise disease treatment and care with long standing, potentially disease curing approaches to a wide range of otherwise untreatable diseases.

Keywords: Gene Therapy, Genome Editing, CRISPR, Precision Medicine, RNA Therapeutics, Viral Vectors, Artificial Intelligence, Personalized Medicine, Clinical Applications, Genetic Disorders

How to cite this article:
Gaurav Kumar Mahto, Tanya Sharma, Shubam Singh, Kamalesh Mistry, Md. Aftab Alam, Neha Nahid. Gene Therapy 2.0: Harnessing Cutting-Edge Technologies for Precision Medicine. International Journal of Genetic Modifications and Recombinations. 2025; 03(02):-.
How to cite this URL:
Gaurav Kumar Mahto, Tanya Sharma, Shubam Singh, Kamalesh Mistry, Md. Aftab Alam, Neha Nahid. Gene Therapy 2.0: Harnessing Cutting-Edge Technologies for Precision Medicine. International Journal of Genetic Modifications and Recombinations. 2025; 03(02):-. Available from: https://journals.stmjournals.com/ijgmr/article=2025/view=228328


References

  1. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-60.
  2. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672.
  3. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53.
  4. Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63-89.
  5. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502.
  6. Dunbar CE, Kohn DB, Schiffman JD, Sievers EL, Gary DJ. Gene therapy for hematologic malignancies. Mol Ther. 2021;29(2):369-88.
  7. Liu X, Hao M, Chen Z, Abudumijiti H, Wei X, Ma L, et al. Advances in non-viral gene delivery systems for cancer therapy. Biomater Sci. 2022;10(2):409-25.
  8. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-41.
  9. Kantor B, Bailey RM, Wimberly K, Kalburgi SN, Gray SJ. Methods for gene transfer to the central nervous system. Adv Genet. 2014;87:125-97.
  10. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397-405.
  11. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78.
  12. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-54.
  13. Schott JW, Morgan MA, Galla M. Viral and non-viral approaches for transient reprogramming of the genome. Curr Opin Biotechnol. 2021;70:154-64.
  14. Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920-6.
  15. Sharma A, Sharma R, Singh V. Advances in gene therapy for inherited eye diseases. Indian J Ophthalmol. 2021;69(4):635-48.
  16. Ayuso C, Mingozzi F. Pharmacogenomics of gene therapy for inherited retinal diseases. Hum Genet. 2021;140(6):825-39.
  17. Kantor A, McClements ME, MacLaren RE. CRISPR-Cas9 DNA base-editing and prime-editing: principles and applications. Nat Rev Mol Cell Biol. 2020;21(8):556-77.
  18. Musunuru K. The hope and hype of CRISPR-Cas9 genome editing: a review. JAMA Cardiol. 2017;2(8):914-9.
  19. Hendriks WT, Warren CR, Cowan CA, Rinn JL. Genome editing technologies for stem cell engineering. Genome Biol. 2016;17(1):238.
  20. Wu Y, Li Y, Zhang F, Chen X, Wang Y, Liu J, et al. Transposon-based gene delivery systems in gene therapy. Cancer Gene Ther. 2021;28(3-4):132-49.
  21. Angelis E, Das S. Clinical translation of gene therapy in heart failure. Curr Heart Fail Rep. 2020;17(3):113-23.
  22. Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10(6):740-9.
  23. Wilkinson D, Thomas M, Herrmann D, et al. The clinical implementation of personalized medicine: a gene therapy perspective. Front Med. 2021;8:647222.
  24. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.
  25. Ylä-Herttuala S. Endgame: gene therapy for cardiovascular diseases. Circulation. 2015;131(15):1380-92.
  26. Simioni P, Tormene D, Gavasso S, Pollio G, Prandoni P. Gene therapy for hemophilia: state of the art and challenges ahead. J Thromb Haemost. 2021;19(4):1023-31.
  27. Chandrasekharan DP, Ferris ST, Cameron L, Rao H, Colonna M. Gene therapy for primary immunodeficiencies: progress and challenges. Curr Opin Immunol. 2020;65:74-80.
  28. Baldo A, van den Akker E, Bergmans HE, et al. In situ gene therapy for muscular dystrophies: optimizing vector delivery and efficacy. Hum Gene Ther. 2020;31(19-20):1012-28.
  29. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014;20(35):5507-9.
  30. Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.
  31. Wang P, Zhao W, Zhao D, et al. RNA-based therapeutics for neurodegenerative diseases. Mol Ther. 2022;30(1):186-206.
  32. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
  33. Chu VT, Weber T, Graf R, et al. Efficient conditional knockout of genes in primary B cells using CRISPR/Cas9. Proc Natl Acad Sci U S A. 2015;112(32):10437-42.
  34. Jain R, Pandey R, Tripathi Y. Synthetic biology approaches in gene therapy. ACS Synth Biol. 2018;7(7):1695-711.
  35. Chen Y, Liu X, Yin X, et al. Advances in nanotechnology for gene delivery and cancer therapy. Nano Today. 2021;37:101105.
  36. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121-31.
  37. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7.
  38. Zhang Y, Li X, Zhang Y, et al. Advances in gene therapy for neurodegenerative diseases. Neurosci Bull. 2020;36(6):596-613.
  39. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Mol Ther. 2013;21(6):1187-94.
  40. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9(1):60.
Ahead of Print Subscription Review Article
Volume 03
02
Received 10/04/2025
Accepted 19/04/2025
Published 29/09/2025
Publication Time 172 Days
126

Login


My IP

PlumX Metrics